These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32880796)

  • 1. Differentiating biochemical from clinical heparin resistance in COVID-19.
    Lisman T; Thachil J
    J Thromb Thrombolysis; 2020 Nov; 50(4):1015-1016. PubMed ID: 32880796
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care.
    Thomas W; White D; Cox-Morton S; MacDonald S; Besser M
    Thromb Res; 2020 Nov; 195():226-227. PubMed ID: 32795720
    [No Abstract]   [Full Text] [Related]  

  • 3. A Case of Covid-19 Patient with Acute Limb Ischemia and Heparin Resistance.
    Baccellieri D; Bilman V; Apruzzi L; Monaco F; D'Angelo A; Loschi D; Melissano G; Chiesa R
    Ann Vasc Surg; 2020 Oct; 68():88-92. PubMed ID: 32589931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.
    Menezes-Rodrigues FS; Padrão Tavares JG; Pires de Oliveira M; Guzella de Carvalho R; Ruggero Errante P; Omar Taha M; José Fagundes D; Caricati-Neto A
    J Thromb Haemost; 2020 Aug; 18(8):2073-2075. PubMed ID: 32408391
    [No Abstract]   [Full Text] [Related]  

  • 5. The versatile heparin in COVID-19.
    Thachil J
    J Thromb Haemost; 2020 May; 18(5):1020-1022. PubMed ID: 32239799
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
    Cattaneo M; Bertinato EM; Birocchi S; Brizio C; Malavolta D; Manzoni M; Muscarella G; Orlandi M
    Thromb Haemost; 2020 Aug; 120(8):1230-1232. PubMed ID: 32349132
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential of heparin and nafamostat combination therapy for COVID-19.
    Asakura H; Ogawa H
    J Thromb Haemost; 2020 Jun; 18(6):1521-1522. PubMed ID: 32302456
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis.
    Perna AF; Capolongo G; Trepiccione F; Simeoni M; Zacchia M; Ingrosso D
    Kidney Blood Press Res; 2020; 45(3):357-362. PubMed ID: 32450560
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin.
    Hosseini A; Bahramnezhad F
    Sao Paulo Med J; 2020; 138(4):349-351. PubMed ID: 32813845
    [No Abstract]   [Full Text] [Related]  

  • 10. Type and dose of heparin in Covid-19: Reply.
    Thachil J; Tang N; Gando S; Falanga A; Levi M; Clark C; Iba T; Cattaneo M
    J Thromb Haemost; 2020 Aug; 18(8):2063-2064. PubMed ID: 32329221
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.
    Conzelmann C; Müller JA; Perkhofer L; Sparrer KM; Zelikin AN; Münch J; Kleger A
    Clin Med (Lond); 2020 Nov; 20(6):e218-e221. PubMed ID: 32863274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy.
    Dragonetti D; Guarini G; Pizzuti M
    Blood Transfus; 2020 Jul; 18(4):328. PubMed ID: 32697931
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?
    Ahmed S; Anirvan P
    Clin Rheumatol; 2020 Jul; 39(7):2099-2100. PubMed ID: 32388748
    [No Abstract]   [Full Text] [Related]  

  • 14. The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.
    Canonico ME; Siciliano R; Scudiero F; Sanna GD; Parodi G
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):262-264. PubMed ID: 32383737
    [No Abstract]   [Full Text] [Related]  

  • 15. Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy.
    Giusti B; Gori AM; Alessi M; Rogolino A; Lotti E; Poli D; Sticchi E; Bartoloni A; Morettini A; Nozzoli C; Peris A; Pieralli F; Poggesi L; Marchionni N; Marcucci R
    Thromb Haemost; 2020 Aug; 120(8):1233-1236. PubMed ID: 32455440
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
    Ferrandis R; Llau JV; Quintana M; Sierra P; Hidalgo F; Cassinello C; Gómez-Luque A
    Crit Care; 2020 Jun; 24(1):332. PubMed ID: 32527286
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?
    Pisani A; Rizzo M; Angelucci V; Riccio E
    Nephron; 2020; 144(8):383-385. PubMed ID: 32526763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease.
    Lozano R; Franco ME
    Med Clin (Barc); 2020 Nov; 155(9):409-410. PubMed ID: 32883507
    [No Abstract]   [Full Text] [Related]  

  • 19. Inaccurate conclusions by Tang and colleagues.
    Greenstein YY
    J Thromb Haemost; 2020 Jul; 18(7):1797. PubMed ID: 32304156
    [No Abstract]   [Full Text] [Related]  

  • 20. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.
    Testa S; Paoletti O; Giorgi-Pierfranceschi M; Pan A
    Intern Emerg Med; 2020 Aug; 15(5):751-753. PubMed ID: 32297089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.